Apart from Victoza, which was approved for Type 2 diabetes in 2010, liraglutide also underpins Novo’s older weight loss drug Saxenda and its insulin-degludec-based diabetes combination therapy ...

Eligible participants were randomly assigned (1:1) with the use of a block design separately for each site to either the TI-degludec regimen or the usual care (UC) group. HbA1c was measured at ...